NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib

CompletedOBSERVATIONAL
Enrollment

214

Participants

Timeline

Start Date

January 21, 2021

Primary Completion Date

May 14, 2025

Study Completion Date

May 14, 2025

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

OFEV®

nintedanib

Trial Locations (26)

100

National Taiwan University Hospital, Taipei

110

Taipei Medical University Hospital, Taipei

111

Shin Kong Wu Ho-Su Memorial Hospital, Taipei

114

Tri-Service General Hospital, Taipei

231

Taipei Tzu Chi General Hospital, New Taipei City

235

Taipei Medical University-Shuang Ho Hospital, New Taipei City

300

National Taiwan University Hospital-Hsin-Chu Branch, Hsinchu

330

Chang Gung Memorial Hospital(Linkou), Taoyuan District

407

Cheng Ching Hospital, Taichung

413

Asia University Hospital, Taichung

500

Chang-Hua Christian Hospital, Changhua

613

Chang Gung Memorial Hospital Chiayi, Chiayi City

632

National Taiwan University Hospital Yun-Lin Branch, Yunlin County

807

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

824

E-Da Hospital, Kaohsiung City

950

Taitung MacKay Memorial Hospital, Taitung

10449

Mackay Memorial Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

26058

National Yang-Ming University Hospital, Yilan

40201

Chung Shan Medical University Hospital, Taichung

40705

Taichung Veterans General Hospital, Taichung

81362

Kaohsiung Veterans General Hospital, Kaohsiung City

83301

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

404327

China Medical University Hospital, Taichung

Unknown

Cheng Hsin Rehabilitation Medical Center, Taipei

TaoYuan General Hospital, Taoyuan

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04614441 - NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib | Biotech Hunter | Biotech Hunter